Abstract: Provided herein are compositions comprising ruboxistaurin free base and its salts thereof and methods of use for treating conditions of the skin.

Abstract: The present disclosure relates to a composition for preventing, alleviating, or treating allodynia caused by anticancer agents, containing cinnamic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition of the present disclosure can prevent, alleviate, or treat allodynia by being administered to a subject scheduled to receive anticancer agents or having received anticancer agents.

Abstract: To provide a hard capsule composed of a hard capsule film that can be molded by a cold gelation method and has enteric properties.

Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.

Abstract: The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.

Abstract: An object of the present invention is to provide a spraying agent containing a pesticide having a higher pesticidal effect. The spraying agent of the embodiment of the present invention is characterized by being an aqueous solution containing, as the pesticide, boric acid that acts as a food poison for pests (for example, red mites) and an alkali metal silicate that acts as a spiracle barrier and a migration suppressor for pests, and further containing at least one of a protein and a carbohydrate for acting to attract or feed the pests, and an emulsifier or a surfactant and a fat and oil having an effect of removing the oil or fat on the epidermis of the pests.

Abstract: Antimicrobial pharmaceutical compositions are formulated to allow local application in vivo of doses that provide antimicrobial effectiveness with low risk of local tissue toxicities and/or low risk of systemic/distant organ toxicities. In various embodiments the antimicrobial pharmaceutical compositions comprise antimicrobial synthetic cationic polypeptide(s) that are dispersed in an aqueous carrier and formulated to achieve a desired degree of polymer self-assembly and/or composition viscosity.

Abstract: A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected.

Abstract: The present invention is directed to a dispensing device comprising: an ophthalmic liquid composition comprising a prostaglandin analogue; a container with the ophthalmic liquid composition comprising a prostaglandin analogue packaged therein; a dropper; and a gasket, wherein the gasket is made of a polymer substantially free of ethylene-vinyl acetate or plasticiser. The present invention further refers to a dropper and a gasket for the dispensing device and to a preservative-free aqueous ophthalmic composition of latanoprost.

Abstract: A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.

Abstract: The present invention discloses a composition comprising neratinib, or a pharmaceutically acceptable salt thereof, and hydroxypropyl-?-cyclodextrin, a method for preparing same, and use thereof. Study results show that the present invention can not only significantly improve the bioavailability of the active ingredient, but also eliminate food effects and adverse event diarrhea.

Abstract: The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.

Abstract: Disclosed herein are novel wavy, multi-component vascular grafts (WMVGs) with a wavy inner layer of rigid biopolymer fibers and an outer layer of elastic biopolymer fibers and a method for preparing WMVGs via electrospinning using a special assembled collector. The fabricated WMVGs closely mimic the non-linear tensile stress-strain relationship of native blood vessels and showed sufficient mechanical strength needed for implantation.

Abstract: By the ingestion of dosage forms containing sparingly water-soluble drug particles, it is not possible to deliver drug into the blood stream at high rates, because the drug dissolution rate, and the absorption rate, are limited by solubility. Herein, therefore, dosage forms comprising a slender, three-dimensional structural framework of sparingly-soluble drug dissolved in an excipient matrix comprising at least a water-soluble polymer carrier and an amphiphilic polymer are disclosed. Upon immersion in a physiological fluid, said fluid wets the structural framework, interdiffuses with it, and the amphiphilic polymer self-assembles as micelles, thereby enhancing drug solubility. Concomitantly, the framework erodes and rapidly releases drug molecules, thus enhancing drug concentration in the fluid and the drug delivery rate into the blood stream.

Abstract: A pharmaceutical composition for treating or improving edema and blood stasis after open surgery according to an embodiment of the present disclosure includes an extract of a mixed herbal medicine including Prunus persica Batsch, Carthamus tinctorius Linni, and Moutan radicis Cortex as an active ingredient.

Abstract: The invention is used in conducting intestinal lavage and enteral correction of body homeostasis disorders, shortening a regeneration period of the mucosa of the gastrointestinal tract (GIT), reducing a rate of extraintestinal complications related to hyperpermeability of the intestinal barrier, and preventing edemas after intestinal lavage at various diseases. The invention includes an acid-mineral composition (AMC) and a solution of sodium phosphate mono-, or twice-, or triple-substituted, or potassium phosphate mono- or twice-substituted, sodium chloride, sodium acetate, potassium chloride, calcium chloride, magnesium sulphate, citric acid, and water. The osmolarity of the solution is preferably in the range from 280 to 310 mOsm/L. The invention may further comprise aminopolycarboxylic acids and short-chain carboxylic (fatty) acids to provide a solution pH from 4.61 to 5.8.

Abstract: The invention provides a constituent that is used with a novel method for preventing and/or treating skin wounds and ensures stable delivery of low-concentration hydrogen sulfide to a wound site. The skin wound-preventing and/or treating constituent includes a sustained hydrogen sulfide releasing agent that is preferably a layered double hydroxide having HS— and/or Sk2- between layers where k is a positive integer.

Abstract: The present invention relates to a combustible and edible composition comprising medium-chain triacylglycerols and silica, wherein the composition is in one embodiment a solid shaped body. The invention further relates to the use of a composition or of a solid shaped body as an item of equipment for outdoor activities, camping, sports activities, and/or in a diet.

Abstract: A composition has an enzyme that is able to convert a substrate to release hydrogen peroxide; a substrate for the enzyme; and a superabsorbent component, such as a superabsorbent polymer. The composition is in the form of a powder and may form a gel on contact with water.

Abstract: An aqueous liquid cosmetic containing 1 to 20% by mass of (A) a flake aluminum powder coated with a layer containing a silicon compound; 0.5 to 10% by mass of (B) a polycarboxylic acid-based dispersant having a mass-average molecular weight of 10,000 or less; and 1 to 40% by mass of (C) a film-forming polymer emulsion in terms of a solid content is provide. Normally, the aqueous liquid cosmetic contains at least 40% by mass of water, and further may optionally contain (D) a color pigment as another ingredient. This aqueous liquid cosmetic is suitable for eye makeup applications such as eyeliners, eyebrows, eye colors, and the like.